Screener
Ultragenyx Pharmaceutical RARE Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333233
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Selling, general and administrative | 88 | 87 | 176 | 174 |
| Total operating expenses | 289 | 275 | 594 | 557 |
| Loss from operations | (75) | (108) | (244) | (251) |
| Interest income | 5 | 6 | 11 | 13 |
| Non-cash interest expense on liabilities for sales of future royalties | (22) | (14) | (43) | (28) |
| Other income | 1 | 2 | 1 | 2 |
| Loss before income taxes | (91) | (114) | (275) | (264) |
| Provision for income taxes | (1) | (1) | (2) | (2) |
Item 1. Financial Statements
FAQ
- What is Ultragenyx Pharmaceutical's interest income?
- Ultragenyx Pharmaceutical (RARE) reported interest income of $5M in Q2 2026.
- How has Ultragenyx Pharmaceutical's interest income changed year-over-year?
- Ultragenyx Pharmaceutical's interest income decreased by 16.7% year-over-year, from $6M to $5M.
- What is the long-term trend for Ultragenyx Pharmaceutical's interest income?
- Over 4 years (2021 to 2025), Ultragenyx Pharmaceutical's interest income has grown at a 90.5% compound annual growth rate (CAGR), from $1.93M to $25.38M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Ultragenyx Pharmaceutical's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude